Abstr#548: Efficacy and safety of subcut CT-P13 (IFX biosimilar) 1 year after switching from IV CT-P13 in pts with RA. Non-inferiority of efficacy (decrease in baseline DAS28-CRP) at wk 22 achieved. Safety same. Another alt convenient way of administration? #ACR2019 @RheumNow